There was a lot of excitement when teprotumumab-trbw became the first drug approved for the treatment of thyroid eye disease in January 2020.
The availability of teprotumumab-trbw (Tepezza, Amgen) has changed the landscape of treatment in thyroid eye disease.
Image: Eisha Gupta, MD. Printed with permission.
“Tepezza has been a game changer in how thyroid eye disease is now managed,” Arti Bhan, MD, FACE, a Healio | Endocrine Today Editorial Board Member and division head of endocrinology at Henry Ford Health System, said in an interview. “We have patients who have high clinical activity scores